Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy

Company Overview - Nuvation Bio is a clinical-stage biotechnology company focused on developing innovative oncology therapeutics, leveraging a pipeline of small molecule inhibitors and drug conjugate platforms to address significant gaps in cancer care [5][8] - The company has a market capitalization of $1.4 billion and reported revenue of $26.75 million for the trailing twelve months (TTM), with a net income loss of $217.48 million for the same period [4] Recent Transaction - On February 17, 2026, Knoll Capital Management disclosed the purchase of 473,591 shares of Nuvation Bio, with an estimated transaction value of $2.93 million based on quarterly average pricing [1][2] - Following this transaction, Knoll Capital's total holdings in Nuvation Bio increased to 1,498,591 shares, with the value of the position rising by $7.88 million from the previous report due to both the additional purchase and price appreciation [2] Financial Performance - Nuvation Bio's shares were priced at $4.25 as of February 17, 2026, reflecting a 130% increase over the past year, significantly outperforming the S&P 500's approximately 16% gain during the same period [7] - The company ended 2025 with $529.2 million in cash and marketable securities, while IBTROZI generated $15.7 million in net product revenue for the fourth quarter and $24.7 million for the year [9] Investment Implications - The investment thesis for long-term investors relies on the durable uptake of IBTROZI and progress in the Phase 3 SIGMA trial, with the company's balance sheet providing flexibility [11] - Despite revenue growth, Nuvation Bio reported a full-year net loss of $204.6 million, attributed to increased R&D and commercialization spending, which is typical for companies transitioning from pipeline to product [10]